Synonyms: alflutinib (pseudo INN) | ASK120067 | AST-2818 | AST2818 | example 3 [US10072002B2] | furmonertinib | Ivesa®
firmonertinib is an approved drug (China (2021))
Compound class:
Synthetic organic
Comment: Firmonertinib (AST2818; formerly furmonertinib) is a receptor tyrosine kinase inhibitor that targets mutant forms of the EGFR more effectively than the wild type receptor kinase, with notable potency vs. the T790M resistance mutation. Firmonertinib is the formal WHO INN. It has an irreversible binding mode. AST2818's chemical structure is claimed as example 3 in Shanghai Allist Pharmaceuticals' patent US10072002B2 [2]. Note that AST2818 is administered clinically as the mesylate.
|
|
References |
1. Deeks ED. (2021)
Furmonertinib: First Approval. Drugs, 81 (15): 1775-1780. [PMID:34528187] |
2. Luo H, Zhou H, Wang S, Wu Y. (2018)
Pyridinylaminopyrimidine derivatives, preparation process and use thereof. Patent number: US10072002B2. Assignee: Shanghai Allist Pharmaceuticals Inc. Priority date: 21/04/2015. Publication date: 11/09/2018. |